At the 2026 American Academy of Dermatology Annual Meeting, pediatric acne and rosacea care focused on spotting childhood disease early because it differs from adult disease. According to the AAD preview shared via Newswise, pediatric dermatologist Dawn Eichenfield of Rady Children's Hospital-San Diego was slated to explain those differences and why early diagnosis matters. Pediatric acne means pimples, blackheads, cysts, or nodules in newborns through preteens. Pediatric rosacea means persistent facial redness with bumps, visible vessels, and often eye irritation in children.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How is acne staged in children?
- Which treatments apply from age 9?
- What did AAD 2026 add on spironolactone?
- Why is pediatric rosacea still difficult?
How is acne staged in children?
Doctors group pediatric acne by age: neonatal, infantile, mid-childhood from age 1 to under 7, preadolescent from 7 to 12, and adolescent disease. Mid-childhood acne is uncommon and raises concern for an endocrine abnormality.
Practical guidance directs mid-childhood acne to growth-chart review, androgen and bone-age assessment, and referral to pediatric endocrinology. Neonatal lesions usually resolve without treatment.
- newborn pimples that fade in weeks: often observation
- acne at ages 1 to under 7: prompt pediatric visit with growth and hormone check
- acne at ages 7 to 12: routine acne evaluation, with earlier visit if severe, scarring, or excess hair growth
Which treatments apply from age 9?
The current AAD acne guideline strongly recommends benzoyl peroxide, topical retinoids, topical antibiotics and fixed-dose combinations, plus oral doxycycline, for patients age 9 and older, as summarized by HCPLive in January 2024 AAD acne guideline summary. Fixed-dose combinations pair two actives, such as retinoid plus benzoyl peroxide, to improve clearing and simplify routines.
The same guideline, described by Clinician Reviews/MDedge, strongly recommends oral isotretinoin for severe acne and conditionally recommends clascoterone, salicylic and azelaic acids, minocycline or sarecycline, combined contraceptives, and spironolactone AAD recommendations overview. Strong means benefits clearly outweigh risks; conditional means the choice depends more on severity, preferences, and side effects.
What did AAD 2026 add on spironolactone?
At AAD 2026, John Barbieri of Brigham and Women's Hospital updated spironolactone for acne, according to Managed Healthcare Executive spironolactone update from AAD 2026. He noted antiandrogen effects, slow uptake because large trials are lacking, and limited value of routine potassium monitoring.
For readers, that means spironolactone remains an option mainly for acne linked to androgen sensitivity, such as jawline breakouts around periods. Families considering it can ask about blood pressure, dizziness, breast tenderness, interactions, and pregnancy precautions, plus how long a trial should last before judging benefit.
Why is pediatric rosacea still difficult?
Pediatric rosacea affects under 1% of children, lacks established diagnostic criteria and pediatric-specific guidelines, is often underdiagnosed, and frequently involves eye disease. Eyelid care plus antibiotics are commonly needed when eyes are red, gritty, styes recur, or vision blurs.
Drug approvals add another limit: most acne drugs are approved from age 12 upward with sparse preadolescent data, and pediatric rosacea care is often extrapolated from adult regimens and small series where doxycycline was most reported. A child with mid-childhood acne, severe or scarring preteen acne, suspected rosacea, or eye symptoms benefits from referral to pediatric dermatology, with endocrinology or eye care when indicated.
You Might Also Like
- Pediatric Acne and Rosacea at the 2026 AAD Annual Meeting: Scarring and Pigment-Change Questions for Pediatric Dermatology Patients
- Pediatric Acne and Rosacea at the 2026 AAD Annual Meeting: A Source-Checked 2026 Briefing for Pediatric Dermatology Patients
- Individualized Pediatric Acne Care Discussed at AAD 2026: A Source-Checked 2026 Briefing for Parents of Children With Acne